In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

CHICAGO -- Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with ...

1 The data show a strong and improving overall survival (OS) trend favouring amivantamab plus lazertinib at approximately three years of follow-up. 1 These results were presented in a late ...

14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT ® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 ...

08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line ...